Literature DB >> 22238228

Long-term propensity score-matched comparison of percutaneous closure of patent foramen ovale with medical treatment after paradoxical embolism.

Andreas Wahl1, Peter Jüni, Marie-Luise Mono, Bindu Kalesan, Fabien Praz, Laura Geister, Lorenz Räber, Krassen Nedeltchev, Heinrich P Mattle, Stephan Windecker, Bernhard Meier.   

Abstract

BACKGROUND: Patients with ischemic stroke or transient ischemic attack presumably related to patent foramen ovale (PFO) are at risk for recurrent cerebrovascular events. Differences in long-term clinical outcome were investigated among patients with percutaneous PFO closure and those who received medical treatment. METHODS AND
RESULTS: Between 1994 and 2000, 308 consecutive patients with cerebrovascular events presumably related to PFO underwent either percutaneous PFO closure (150 patients) or medical treatment (158 patients). Patients were followed up prospectively for up to 15 years. Seven patients were lost during follow-up. The primary outcome was a composite of stroke, transient ischemic attack, or peripheral embolism. We analyzed 103 propensity score-matched pairs of patients who underwent percutaneous PFO closure or medical treatment. At a median follow-up of 9 years, the primary composite outcome occurred in 11 patients slated to PFO closure (11%) and 22 patients slated to medical treatment (21%; hazard ratio=0.43; 95% confidence interval=0.20-0.94; P=0.033). The treatment effect was driven by a decrease in the risk of transient ischemic attack of 5% versus 14%, respectively (hazard ratio=0.31; 95% confidence interval=0.10-0.94; P=0.039). The risk of all-cause (6% in both groups) and cardiovascular (3% in both groups) mortality appeared to be identical.
CONCLUSION: In this long-term observational, propensity score-matched study, percutaneous PFO closure was more effective than medical treatment for the secondary prevention of recurrent cerebrovascular events among patients with PFO-related transient ischemic attack or stroke.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22238228     DOI: 10.1161/CIRCULATIONAHA.111.030494

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  34 in total

1.  Congenital heart conditions: Patent foramen ovale closure--not all devices are equal.

Authors:  Bernhard Meier
Journal:  Nat Rev Cardiol       Date:  2013-09-03       Impact factor: 32.419

2.  PFO and ASD Closure in Adulthood: Where Do We Stand?

Authors:  Asad A Rizvi; Ronan Margey
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-04

3.  Percutaneous closure of patent foramen ovale: "Closed" door after the last randomized trials?

Authors:  Joel Hernandez; Raul Moreno
Journal:  World J Cardiol       Date:  2014-01-26

Review 4.  [Patent foramen ovale with a license to kill].

Authors:  B Meier
Journal:  Med Klin Intensivmed Notfmed       Date:  2019-03-11       Impact factor: 0.840

5.  PFO Closure for Cryptogenic Stroke: Review of New Data and Results.

Authors:  Shyam Rao; Cathy Sila
Journal:  Curr Treat Options Cardiovasc Med       Date:  2013-06

6.  Patent foramen ovale closure for patients with cryptogenic stroke: A systematic review and comprehensive meta-analysis of 5 randomized controlled trials and 14 observational studies.

Authors:  Xi Chen; Shi-Dong Chen; Yi Dong; Qiang Dong
Journal:  CNS Neurosci Ther       Date:  2018-05-27       Impact factor: 5.243

7.  Safety Outcomes After Percutaneous Transcatheter Closure of Patent Foramen Ovale.

Authors:  Alexander E Merkler; Gino Gialdini; Shadi Yaghi; Peter M Okin; Costantino Iadecola; Babak B Navi; Hooman Kamel
Journal:  Stroke       Date:  2017-09-22       Impact factor: 7.914

Review 8.  Management of the stroke patient with patent foramen ovale: new insights and persistent questions in the wake of recent randomized trials.

Authors:  Jessica M Peña; Jorge R Kizer
Journal:  Curr Atheroscler Rep       Date:  2013-07       Impact factor: 5.113

9.  [Heart or brain? Problem patients at the interface between cardiology and neurology].

Authors:  K Gröschel; J Röther; U Laufs; R Wachter
Journal:  Herz       Date:  2013-06       Impact factor: 1.443

10.  Implantable cardiac devices with patent foramen ovale--a risk factor for cardioembolic stroke?

Authors:  Christopher V DeSimone; Daniel C DeSimone; Nikhil A Patel; Paul A Friedman; Samuel J Asirvatham
Journal:  J Interv Card Electrophysiol       Date:  2012-08-07       Impact factor: 1.900

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.